Citations Appearing in 1996

  1. Abbruzzese, J.L., T. Madden, S.M. Sugarman, R.A. Newman, M.N. Raber, M.N. Zwelling and M.N. Raber. Phase I clinical, plasma, and cellular pharmacologic study of Topotecan without and with granulocyte colony stimulating factor. Clinical Cancer Research 2:1489-1499, 1996.
  2. Aboagye, E.O., A.D. Lewis, M.A. Graham, M. Tracy, A.B. Kelson, K.J. Ryan and P. Workman. The pharmacokinetics, bioavailability and biodistribution in mice of a rationally designed 2-nitroimidazole hypoxia probe Sr-4554. Anti-Cancer Drug Design 11:231-242, 1996.
  3. Amsden, G.W. and C.H. Ballow. Prospective validation of an optimal sparse plasma sampling strategy for estimating ciprofioxacin pharmacokine. Pharmacotherapy 16(5):937- 941, 1996.
  4. Baker, S.D., R.L. Heideman, W.R. Crom, J.F. Kuttesch, A. Gajjar and C.F. Stewart. Cerebro-spinal-fluid pharmacokinetics and penetration of continuous-infusion Topotecan in children with central nervous-system tumors. Cancer Chemotherapy and Pharmacology 37:195-202, 1996.
  5. Balthasar, J.P. and H.L. Fung. Inverse targeting of peritoneal tumors: Selective alteration of the disposition of methotrexate through the use of anti-methotrexate antibodies and antibody fragments. Journal of Pharmaceutical Sciences 85(10):1035-1043, 1996.
  6. Baselga, J., D. Tripathy, J. Mendelsohn, S. Baughman, C.C. Benz, L. Dantis, N.T. Sklarin, A.D. Seidman, C.A. Hudis, J. Moore, P.P. Rosen, T. Twaddell, I.C. Henderson and L. Norton. Phase II study of weekly intravenous recombinant humanized anti- P185(Her2) monoclonal antibody in patients with Her2/Neu-overexpressing metastatic breast. Journal of Clinical Oncology 14:737-744, 1996.
  7. Bilello, J.A., P.A. Bilello, K. Stellrecht, J. Leonard, D.W. Norbeck, D.J. Kempf, T. Robins and G.L. Drusano. Human serum alpha(1) acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type-1 protease. Antimicrobial Agents and Chemotherapy 40:1491-1497, 1996.
  8. Drouin, R., H. Rodriguez, S.W. Gao, Z. Gebreyes, T.R. Oconnor, G.P. Holmquist and S.A. Akman. Cupric ion ascorbate hydrogen peroxide induced DNA damage DNA bound copper ion primarily induces base modifications. Free Radical Biology and Medicine 21:261-273, 1996.
  9. Drusano, G.L., F. Aweeka, J. Gambertoglio, M. Jacobson, M. Polis, H.C. Lane, C. Eaton and S. Martinmunley. Relationship between foscarnet exposure, base line cytomegalovirus (CMV) blood culture and the time to progression of CMV retinitis in HIV positive patients. AIDS 10:113-119, 1996.
  10. Drusano, G.L., M. Prichard, P.A. Bilello and J.A. Bilello. Modeling combinations of antiretroviral agents in-vitro with integration of pharmacokinetics guidance in regimen choice for clinical trial evaluation. Antimicrobial Agents and Chemotherapy 40:1143- 1147, 1996.
  11. Dutta, S., Y. Matsumoto and W.F. Ebling. Is it possible to estimate the parameters of the sigmoid E(Max) model with truncated data typical of clinical studies. Journal of Pharmaceutical Sciences 85:232-239, 1996.
  12. Egorin, M.J., D.L. Sentz, D.M. Rosen, M.F. Ballesteros, C.M. Kearns, P.S. Callery and J.L. Eisman. Plasma pharmacokinetics, bioavailability, and tissue distribution in CD2F1 mice of halomon (NSC 650893), an antitumor halogenated monoterpene isolated from the red algae, portieria hornemannii. Cancer Chemotherapy and Pharmacology 39:51-60, 1996.
  13. Eiseman, J.L., Z.M. Yuan, N.D. Eddington, D.L. Sentz, P.S. Callery and M.J. Egorin. Plasma pharmacokinetics and urinary excretion of the polyamineanalogue 1,19- bis- (ethylamino)-5,10,15-triazanonadecane in Cd2F1 mice. Cancer Chemotherapy and Pharmacology 38:13-20, 1996.
  14. English, M.W., S.P. Lowis, B. Peng, A. Boddy, D.R. Newell, L. Price and A.D.J. Pearson. Pharmacokinetically guided dosing of carboplatin and etoposide during peritoneal dialysis and hemodialysis. British Journal of Cancer 73:776-780, 1996.
  15. Fassos, F.F., J. Klein, D. Fernandes, D. Matsui, N.F. Olivieri and G. Koren. The pharmacokinetics and pharmacodynamics of the oral iron chelator deferiprone (L1) in relation to hemoglobin levels. International Journal of Clinical Pharmacology and Therapeutics 34:288-292, 1996.
  16. Feng, D.G., S.C. Huang and Z.Z.Wang. An unbiased parametric imaging algorithm for nonuniformly sampled biomedical system parameter estimation. IEEE Transactions on Medical Imaging 15:512-518, 1996.
  17. Fleming, R.A., J.M. Cruz, C.D. Webb, G.L. Kucera, J.J. Perry and D.D. Hurd. Urinary elimination of cyclophosphamide alkylating metabolites and free thiols following 2 administration schedules of high dose cyclophosphamide and mesna. Bone Marrow Transplantation 17:497-501, 1996.
  18. Fox, J.A., T.E. Hotaling, C. Struble, J. Ruppel, D.J. Bates and M.B. Schoenhoff. Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. Journal of Pharmacology and Experimental Therapeutics 279(2):1000-1008, 1996.
  19. Fullerton, T., A. Forrest and G. Levy. Pharmacodynamic analysis of sparse data from concentration controlled and effect controlled clinical trials guided by a pilot study – an investigation by simulations. Journal of Pharmaceutical Sciences 85:600-607, 1996.
  20. Furman, W.L., S.D. Baker, C.B. Pratt, G.K. Rivera, W.E. Evans and C.F. Stewart. Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia. Journal of Clinical Oncology 14:1504-1511, 1996.
  21. Gibbons, J.A., A.A. Hancock, C.R. Vitt, S. Knepper, S.A. Buckner, M.E. Brune, I. Milicic, J.F. Kerwin, L.S. Richter, E.W. Taylor, K.L. Spear, R.N. Zuckermann, D.C. Spellmeyer, R.A. Braeckman and W.H. Moos. Pharmacological characterization of Chir-2279, an N-substituted glycine peptoid with high affinity binding for alpha(1)-adrenoceptors. Journal of Pharmacology and Experimental Therapeutics 277:885- 899, 1996.
  22. Glantz, M.J., H. Choy, C.M. Kearns, B.F. Cole, P. Mills, E.G. Zuhowski, S. Saris, C.H. Rhodes, E. Stopa and M.J. Egorin. Phase-I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas. Journal of Clinical Oncology 14:600-609, 1996.
  23. Holmes, F.A., T. Madden and R.A. Newman, et al. Schedule-dependent alterations of doxorubicin pharmacokinetics by paclitaxel in a phase I trial of paclitaxel and doxorubicin in patients with metastatic breast cancer. Journal of Clinical Oncology14:2713- 2721, 1996.
  24. Hu, S.Z., L. Shivery, A. Raubitschek, M. Sherman, L.E. Williams, J.Y.C. Wong, J.E. Shively and A.M. Wu. Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-C(H)3) which exhibits rapid, high level targeting of xenografts. Cancer Research 56:3055-3061, 1996.
  25. Jaber, L.A., M.P. Ducharme, D.J. Edwards, R. Slaughter and G. Grunberger. The influence of multiple dosing and age on the pharmacokinetics and pharmacodynamics of glipizide in patients with type II diabetes mellitus. Pharmacotherapy 16(5):760-768, 1996.
  26. Jodrell, D.I., L.S. Murray, J. Hawtof, M.A. Graham and M.J. Egorin. A comparison of methods for limited sampling strategy design using data from a phase I trial of the anthrapyrazole Dup-941. Cancer Chemotherapy and Pharmacology 37:356-362, 1996.
  27. Johansen, M.J., S. O’Brien, T. Waddelow and T. Madden. Phase I pharmacokinetic study of pyrazine diazohydioxide using a daily times 5 Bolus schedule in adult refractory leukemia. Proceedings of the American Association of Cancer Research 37:371, 1996.
  28. Jones C.D., H. Sun and E.I. Ette. Designing cross-sectional pharmacokinetic studies; Implications for Pediatric and Animal Studies. Clin. Res. Regul. Affairs 13:133-165, 1996.
  29. Kashuba, A.D.M., C.H. Ballow and A. Forrest. Development and evaluation of a Bayesian pharmacokinetic estimator and optimal, sparse sampling strategies for Ceftazidime. Antimicrobial Agents and Chemotherapy 40:1860-1865, 1996.
  30. Kearns, G.L., W.R. Crom, K.H. Karlson, G.B. Mallory and W.E. Evans. Hepatic drug clearance in patients with mild cystic fibrosis. Clinical Pharmacology and Therapeutics 59:529-540, 1996.
  31. Khan, A.A., J.G. Villablanca, C.P. Reynolds and V.I. Avramis. Pharmacokinetic studies of 13-cis-retinoic add in pediatric patients with neuroblastoma following bone marrow transplantation. Cancer Chemotherapy and Pharmacology 39(2):34-41, 1996.
  32. Kharidia, J. and N.D. Eddington. Application of computer-assisted radiotelemetry in the pharmacokinetic and pharmacodynamic modeling of Procainamide and N-acetylprocainamide. Journal of Pharmaceutical Sciences 85:595-599, 1996.
  33. Kharidia, J. and N.D. Eddington. Effects of Desethylamiodarone on the electrocardiogram in conscious freely moving animals pharmacokinetic and pharmacodynamic modeling using computer assisted radio telemetry. Biopharmaceutics and Drug Disposition 17:93-106, 1996.
  34. Kline, M.W., C.V. Fletcher, M.E. Federici, A.T. Harris, K.D. Evans, V.L. Rutkiewicz, W.T. Shearer and L.M. Dunkle. Combination therapy with Stavudine and Didanosine in children with advanced human immunodeficiency virus infection – pharmacokinetic properties, safety, and immunological and virological effects. Pediatrics 97:886-890, 1996.
  35. Kristensen, K., T. Blemmer, H.R. Angelo, L.L. Christrup, N.E. Drenck, S.N. Rasmussen and P. Sjogren. Stereoselective pharmacokinetics of Methadone in chronic pain patients. Therapeutic Drug Monitoring 18:221-227, 1996.
  36. Landoni, M.F., F.M. Cunningham and P. Lees. Pharmacokinetics and pharmacodynamics of tolfenamic acid in calves. Research in Veterinary Science 61:26-32, 1996.
  37. Liu, T.P., D.J. Buchsbaum, D.T. Curiel, M.B. Khazaeli, R.F. Meredith and A.F. LoBuglio. Simulation of tumor-specific delivery of radioligand comparison of one step, two step, and genetic transduction systems. Journal of Molecular Modeling 2(12):467- 477, 1996.
  38. Marino, E.L., J.M. Jansat and C.F. Lastra. Parameterization by non-linear regression analysis of the active acid metabolite of ebastine using different weighing methods.International Journal of Clinical Pharmacology and Therapeutics 34:546-549, 1996.
  39. Masson, E., M.V. Relling, T.W. Synold, Q. Liu, J.D. Schuetz, J.T. Sandlund, C.H. Pui and W.E. Evans. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in-vivo – a rationale for high dose methotrexate. Journal of Clinical Investigation 97:73-80, 1996.
  40. Matsumoto, Y., I. Yamamoto, Y. Watanabe and M. Matsumoto. Enhancing effect of viscous sodium hyaluronate solution on the rectal absorption of morphine. Biological and Pharmaceutical Bulletin 18:1744-1749, 1996.
  41. Mcleod, H.L., M.A. Graham, S. Aamdal, A. Setanoians, Y. Groot and B. Lund. Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug E09. European Journal of Cancer 32A:1518-1522, 1996.
  42. Northfelt, D.W., F.J. Martin, P. Working, P.A. Volberding, J. Russell, M. Newman, M.A. Amantea and L.D. Kaplan. Doxorubicin encapsulated in liposomes containing surface found polyethylene glycol pharmacokinetics, tumor localization, and safety in patients with AIDS related kaposis sarcoma. Journal of Clinical Pharmacology 36:55- 63, 1996.
  43. Piscitelli, S.C., M.A. Amantea, S. Vogel, C. Bechtel, J.A. Metcalf and J.A. Kovacs. Effects of cytokines on antiviral pharmacokinetics – an alternative approach to assessment of drug-interactions using bioequivalence guidelines. Antimicrobial Agents and Chemotherapy 40:161-165, 1996.
  44. Preston, S.L. and G.L. Drusano. Nonparametric expectation maximization population modeling of ganciclovir. Journal of Clinical Pharmacology 36:301-310, 1996.
  45. Preston, S.L., L.L. Briceland, B.M. Lomaestro, T.S. Lesar, G.R. Bailie and G.L. Drusano. Dosing adjustment of 10 antimicrobials for patients with renal impairment. Annals of Pharmacotherapy 29:1202-1207, 1996.
  46. Relling, M.V., H.H. Mahmoud, C.H. Pui, J.T. Sandlund, G.K. Rivera, R.C. Ribeiro, W.M. Crist and W.E. Evens. Etoposide achieves potentially cytotoxic concentrations in CSF of children with acute lymphoblastic leukemia. Journal of Clinical Oncology 14:399-404, 1996.
  47. Rodman, J.H., B. Robbins, P.M. Flynn and A. Fridland. A systemic and cellular model for zidovudine plasma concentrations and intracellular phosphorylation in patients. Journal of Infectious Diseases 174:490-499, 1996.
  48. Rowinsky, E.K., S.H. Kaufmann, S.D. Baker, L.B. Grochow, T.L. Chen, D. Peereboom, M.K. Bowling, S.E. Sartorius, D.S. Ettinger, A.A. Forastiere and R.C. Donehower. Sequences of Topotecan and Cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. Journal of Clinical Oncology 14(12):3074-3084, 1996.
  49. Schiller, J.H., K.M. Kim, P. Hutson, R. Devore, J. Glick, J. Stewart and D. Johnson. Phase-II study of Topotecan in patients with extensive stage small cell carcinoma of the lung – an eastern cooperative oncology group trial. Journal of Clinical Oncology 14:2345-2352, 1996.
  50. Soraci, A.L., O.N. Mestorino and J.O. Errecalde. Pharmacokinetics of Cefoperazone in horses. Journal of Veterinary Pharmacology and Therapeutics 19:39-43, 1996.
  51. Stein, D.S., D.G. Fish, J.A. Bilello, S.L. Preston, G.L. Martineau and G.L. Drusano. A 24 week open label phase I/II evaluation of the HIV protease inhibitor mK-639 (Indinavir). AIDS 10:485-492, 1996.
  52. Taylor, P.M., F.M. Landoni, C. Deal, C. Pickett, F.S. Aliabadi, R. Foot and P. Lees. Pharmacodynamics and enantioselective pharmacokinetics of carprofen in the cat.Research in Veterinary Sciences 60:144-151, 1996.
  53. Tisdale, J.E., M.P. Ducharme, H. Shimoyama, C.R. Webb, H.N. Sabbah and D.J. Edwards. Electrophysiologic and electrocardiographic pharmacodynamics of cocaine. Pharmacotherapy 16:438-445, 1996.
  54. Tod, M., C. Padoin, C. Minozzi, J. Cougnard and O. Petitjean. Population pharmacokinetic study of isepamicin with intensive care unit patients. Antimicrobial Agents and Chemotherapy 40:983-987, 1996.
  55. Tonda, M.E., R.L. Heideman, W.P. Petros, H.S. Friedman, D.J. Murry and J.H. Rodman. Carboplatin pharmacokinetics in young children with brain tumors. Cancer Chemotherapy and Pharmacology 38:395-400. 1996.
  56. Tonn, G.R., E. Kwan, C. Hall, K.W. Riggs, J.E. Axelson and D.W. Rurak. Hepatic first pass uptake of Diphenhydramine – a comparative study between fetal and adult sheep. Drug Metabolism and Disposition 24:273-281, 1996.
  57. Tubergen, D.G., C.F. Stewart, C.B. Pratt, W.C. Zamboni, N. Winick, V.M. Santana, Z.A. Dryer, J. Kurtzberg, B. Bell, H. Grier and T.J. Vietti. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of Topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study. Journal of Pediatric Hematology Oncology 18(4):352-361, 1996.
  58. Vinks, A.A.T.M.M., J.W. Mouton, D.J. Touw, H.G.M. Heijerman, M. Danhof and W. Bakker. Population pharmacokinetics of Ceftazidime in cystic fibrosis patients analyzed by using a nonparametric algorithm and optimal sampling strategy. Antimicrobial Agents and Chemotherapy 40:1091-1097, 1996.
  59. Wall, S.M., T.Madden, D.A. Molony and T.D. DuBose. Effective clearance of methotrexate using high-flux hemodialysis membranes. American Journal of Kidney Diseases 28:846-857, 1996.
  60. Wu, A.M., W.G. Chen, A. Raubitschek, L.E. Williams, M. Neumaier, R. Fischer, S.Z. Hu, T. OdomMaryon, J.Y.C. Wong and J.E. Shively. Tumor localization of anti- CEA single-chain Fvs: Improved targeting by non-covalent dimers. Immunotechnology 12(1):21-36, 1996.
  61. Xu, Z.X., Y.N. Sun, D.C. Dubois, R.R. Almon and W.J. Jusko. 3rd generation model for corticosteroid pharmacodynamics roles of glucocorticoid receptor messenger RNA and tyrosine aminotransferase messenger RNA in rat liver. Journal of Pharmacokinetics and Biopharmaceutics 23:163-181, 1996.
  62. Yu, L.X., J.R. Crison and G.L. Amidon. Compartmental transit and dispersion model analysis of small intestinal transit flow in humans. International Journal of Pharmaceutics 140:111-118, 1996.
  63. Yu, L.X., E. Lipka, J.R. Crison and G.L. Amidon. Transport approaches to the biopharmaceutical design of oral drug delivery systems prediction of intestinal absorption. Advanced Drug Delivery Reviews 19:359-376, 1996.
  64. Yule, S.M., A.V. Boddy, M. Cole, L. Price, R. Wyllie, M.J. Tasso, A.D.J. Pearson and J.R. Idle. Cyclophosphamide pharmacokinetics in children. British Journal of Clinical Pharmacology 41:13-19, 1996.